NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

CEO John Leonard said the company will focus its resources largely on two late-stage programs amid a “challenging market environment.” Intellia Therapeutics Inc. is shedding employees and ...

It has been many moons since I last held a position in Intellia Therapeutics, Inc. (NASDAQ:NTLA). At that time, cutting-edge biotech companies going after CAR-T therapies and gene therapies were ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...

Intellia Therapeutics shifts focus to NTLA-2002 for hereditary angioedema and nex-z for ATTR amyloidosis, advancing Phase 3 trials in 2025. Strategic reorganization includes a 27% workforce ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep the engine running until a potential commercial launch in 2027.

The inducement grant consisted of time-based restricted stock units (“RSUs”) for 21,863 shares of Intellia’s common stock, with one-third of such RSUs vesting on February 1, 2026, 2027 and 2028.

https://www.tipranks.com/news/the-fly/option-care-health-price-target-raised-to-35-from-30-at-jmp-securities Wells Fargo lowered the firm’s price target on Intellia ...

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...